Skip to main content

Table 5 Development of the different groups at baseline (No work absentism, less than 5 days,...) one year after start of treatment with glatiramer acetate using the same categories (No work absentism, less than 5 days,...).

From: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

Baseline No work absentism ≤ 5 days absent 6–10 days absent 11–20 days absent > 20 days absent Not in employment
After 12 Months N % N % N % N % N % N %
No work absentism 59 21.3% 15 5.4% 20 7.2% 23 8.3% 22 7.9% 9 3.3%
≤ 5 days absent 6 2.2% 8 2.9% 8 2.9% 1 0.4% 4 1.4% 0 0%
6–10 days absent 4 1.4% 1 0.4% 3 1.1% 2 0.7% 4 1.4% 0 0%
11–20 days absent 2 0.7% 2 0.7% 1 0.4% 2 0.7% 1 0.4% 0 0%
> 20 days absent 0 0% 0 0% 3 1.1% 1 0.4% 13 4.7% 1 0.4%
Not in employment 3 1.1% 0 0% 2 0.7% 1 0.4% 4 1.4% 52 18.8%